First‐in‐Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe Disease.

MLA

Ullman, Julie C., et al. “First‐in‐Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe Disease.” Clinical Pharmacology & Therapeutics, vol. 116, no. 6, Dec. 2024, pp. 1580–92. EBSCOhost, https://doi.org/10.1002/cpt.3470.

APA

Ullman, J. C., Dick, R. A., Linzner, D., Minga, T., Tep, S., Satterfield, T. F., Xi, Y., Beattie, D. T., Marmon, T., Neutel, J. M., Chung, B., Leeds, J. M., Noonberg, S. B., Green, E. M., & Bernstein, H. S. (2024). First‐in‐Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe Disease. Clinical Pharmacology & Therapeutics, 116(6), 1580–1592. https://doi.org/10.1002/cpt.3470

Chicago

Ullman, Julie C., Ryan A. Dick, Daniela Linzner, Todd Minga, Samnang Tep, Terrence F. Satterfield, Yannan Xi, et al. 2024. “First‐in‐Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe Disease.” Clinical Pharmacology & Therapeutics 116 (6): 1580–92. doi:10.1002/cpt.3470.